Dobutamine

Generic Name: Dobutamine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₃NO_₃

CAS Number: 34368-04-2

Unique Ingredient Identifier: 3S12J47372

Background: A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

Indication: Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Associated Conditions: Cardiac Decompensation, Coronary Artery Disease (CAD)

Associated Therapies: Intravenous inotropic therapy

Clinical Trials

Dobutamine for Management of Surgical Patients with Septic Shock

Not Applicable

Recruiting

Conditions: Patients with Septic Shock
Surgical Patients
General Anesthesia

Interventions: Drug: Norepinephrine
Drug: Dobutamine

First Posted Date: 2024-06-17

Last Posted Date: 2024-12-04

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 584

Registration Number: NCT06462313

Locations: 🇨🇳
The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

Phase 1

Recruiting

Conditions: ATTR Amyloidosis Wild Type

Interventions: Drug: Dobutrex

First Posted Date: 2024-03-19

Last Posted Date: 2024-04-17

Lead Sponsor: Steen Hvitfeldt Poulsen

Target Recruit Count: 35

Registration Number: NCT06318260

Locations: 🇩🇰
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital

Not Applicable

Not yet recruiting

Conditions: Dobutamine, Milrinone , Pediatrics , Low Cardiac Output

Interventions: Drug: Dobutamine

First Posted Date: 2023-08-21

Last Posted Date: 2023-08-21

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT05999487

Locations: 🇪🇬
Cairo University Children'S Hospital, Giza, Egypt

Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.

Phase 2

Not yet recruiting

Conditions: Hyperlactatemia
Sepsis
Hypoperfusion

Interventions: Drug: Dobutamine

First Posted Date: 2023-07-19

Last Posted Date: 2024-01-30

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 120

Registration Number: NCT05953142

Locations: 🇧🇷
Federal University of São Paulo, São Paulo, Brazil

Consistency of Carotid Doppler Blood Flow and Thermodilution Technique

Not Applicable

Recruiting

Conditions: Cardiac Surgery

Interventions: Behavioral: passive leg raising
Drug: Dobutamine

First Posted Date: 2023-07-13

Last Posted Date: 2023-07-13

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 200

Registration Number: NCT05944146

Locations: 🇨🇳
Zhongshan hospital Fudan University, Shanghai, Shanghai, China

Right Ventricular Contractile Reserve in HF

Not Applicable

Recruiting

Conditions: Heart Failure

Interventions: Drug: Dobutamine
Other: Passive leg raising

First Posted Date: 2023-04-04

Last Posted Date: 2023-04-04

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 60

Registration Number: NCT05797584

Locations: 🇮🇹
Ospedale San Luca IRCCS Istituto Auxologico Italiano, Milan, MI, Italy

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Phase 2

Recruiting

Conditions: Cardiogenic Shock
Acute Myocardial Infarction

Interventions: Drug: Tocilizumab
Drug: Dobutamine
Drug: NaCl 0.9%

First Posted Date: 2022-04-28

Last Posted Date: 2024-11-26

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 100

Registration Number: NCT05350592

Locations: 🇩🇰
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Phase 4

Recruiting

Conditions: Shock, Cardiogenic

Interventions: Drug: Normal Saline
Drug: Dobutamine
Drug: Milrinone

First Posted Date: 2022-03-04

Last Posted Date: 2024-04-08

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 346

Registration Number: NCT05267886

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

Supernormal Oxygen Delivery for Patients With Severe Burns

Early Phase 1

Conditions: Burn Surgery
Dobutamine

Interventions: Drug: Dobutamine

First Posted Date: 2022-02-16

Last Posted Date: 2022-02-16

Lead Sponsor: Guangzhou Red Cross Hospital

Target Recruit Count: 100

Registration Number: NCT05241912

Locations: 🇨🇳
Guangzhou Red cross hospital, Guangzhou, Guangdong, China

Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI

Not Applicable

Completed

Conditions: Cardiovascular Abnormalities

Interventions: Other: Ultrasound
Procedure: Catheters
Procedure: Soft study wire
Radiation: X-ray
Drug: Dobutamine

First Posted Date: 2022-01-19

Last Posted Date: 2024-03-26

Lead Sponsor: The Royal Wolverhampton Hospitals NHS Trust

Target Recruit Count: 7

Registration Number: NCT05196815

Locations: 🇬🇧
The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy